J Exp Med: Reveals the drivers of cytoblastoma and provides new ideas for reducing tumor volume before surgery.

Peripheral transsexual nervous system tumors, including neuroblastoma, ganglioneuroma and ganglioneuroma, are the most common inocranial solid tumors in children.
-sectional cell neuroma originated from nerve cells, although it is a fully differentiated benign tumor, but because of the size of the tumor, often invade adjacent tissue organs, the adjacent soft tissue, blood vessels, nerves and bone has an oppressive effect.
The current treatment of cellular neuroma is limited to surgery, but complete excision is difficult, often resulting in many complications including intestinal dysfunction, surgical wound healing difficulties, and so far there is no effective means of chemotherapy to reduce the size of the tumor before surgery.
, the drivers of cytoblastomas are far from clear compared to neuroblastomas.
, Journal of Analytic Medicine published online the Dana-Farber Oncology Institute at Harvard Medical School. The results of Professor Thomas Look's team (Dr. Tao Ting and Dr. Shi Hui are co-authors of the article): Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR reedors.
study reveals the drivers of cytoblastoma and provides new ideas for reducing tumor volume before surgery.
The authors first analyzed the phosphatized AKT levels of human cytoblastoma and neuroblastoma samples through immunobiochemological staining, and found that 90.91% of the cytoblastoma samples were expressed with medium and high levels of phosphate AKT, while only 6.67% of neuroblastoma samples were able to detect the expression of phosphate AKT.
same time, the detection of AKT downstream effect protein also showed that the positive rate of phosphorylation mTOR and S6 in the samples of cytoblastoma was significantly higher than that of neuroblastoma.
authors then successfully constructed the first zebrafish cell neuroma model using the dopamine-beta-hydroxylase gene launcher to drive continuously activated AKT (myr-AKT) expression.
further studies have found that zebrafish cell neuromas are highly similar to human cytoblastomas in both pathology and transcriptional groups.
using this zebrafish model for drug screening, the authors further clarified that mTOR inhibitors (including sirolimus and everolimus) can effectively reduce the volume of zebrafish cell neuromas, providing a new way of thinking for human cytomebra tumors to reduce tumor volume before surgery.
overall, the study found that akT-mTOR-S6 signal pathways were the driver of cellular neuromas, established the first zebrafish cell neuroma model, and found that mTOR inhibitors significantly reduced the lesions of zebrafish cell neuromas.
Since mTOR inhibitors sirolimus and everolimus have been approved for the treatment of related pediatric diseases, the authors recommend that clinical studies be conducted on these drugs to assess their efficacy in human cytoblastoma for the benefit of the children involved.
.